Research Article
Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
Table 1
Patient demographics and baseline characteristics (
).
| | Characteristic | VTD group () | Improved VTD group () | value |
| | Sex (male/female) | 18/12 | 17/13 | 0.793 | | Median age (years, range) | 54 (31–67) | 57 (34–72) | 0.712 | | Myeloma type | | | | | IgG | 12 (40%) | 14 (46.7%) | 0.602 | | IgA | 9 (30%) | 7 (23.3%) | 0.559 | | IgM | 2 (6.7%) | 3 (10%) | 0.640 | | Light chain | 7 (23.3%) | 6 (20%) | 0.754 | | ISS stage | | | | | I | 6 (20%) | 6 (20%) | 1.000 | | II | 18 (60%) | 15 (50%) | 0.436 | | III | 6 (20%) | 9 (30%) | 0.371 | | Cytogenetics | | | | | Diploid | 15 (50%) | 13 (43.3%) | 0.605 | | Hyperdiploid | 6 (20%) | 7 (23.3%) | 0.754 | | Nonhyperdiploid | 6 (20%) | 8 (26.7%) | 0.542 | | Hypodiploid | 3 (10%) | 2 (6.7%) | 0.640 | | Interphase FISH | | | | | t(4;14) | 15 (50%) | 12 (40%) | 0.436 | | del(17p13) | 9 (30%) | 14 (46.7%) | 0.184 | | t(11;14) | 6 (20%) | 4 (13.3%) | 0.488 | | Hemoglobin (g/L) | 103 (71–144) | 109 (73–159) | 0.677 | | Albumin (g/L) | 37.5 (22–47) | 36 (24–43) | 0.820 | | microglobulin (mg/L) | 3.9 (2.2–16.9) | 4.3 (2.3–18.3) | 0.754 | | Platelets (×109/L) | 243.4 (98.2–602.1) | 251.7 (79.3–533.2) | 0.501 | | Creatinine (mg/dL) | 1.6 (0.4–3.7) | 1.7 (0.2–4.1) | 0.835 |
|
|
